GRM5 and fragile X syndrome: Clinical trials of mGluR5 NAMs for FXS were limited by the variable age groups of study participants, problematic outcome measurements, placebo effects, and potentially the absence of a tool to measure the expression of mGluR5 in the living brains of participants with FXS [2,42,43,44,46,56,57].